213 related articles for article (PubMed ID: 9363867)
41. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
42. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
44. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
45. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Taylor C; Hershman D; Shah N; Suciu-Foca N; Petrylak DP; Taub R; Vahdat L; Cheng B; Pegram M; Knutson KL; Clynes R
Clin Cancer Res; 2007 Sep; 13(17):5133-43. PubMed ID: 17785568
[TBL] [Abstract][Full Text] [Related]
46. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
Poltinnikov IM; Rudoler SB; Tymofyeyev Y; Kennedy J; Anne PR; Curran WJ
Am J Clin Oncol; 2006 Feb; 29(1):71-9. PubMed ID: 16462507
[TBL] [Abstract][Full Text] [Related]
47. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
Disis ML; Goodell V; Schiffman K; Knutson KL
J Clin Immunol; 2004 Sep; 24(5):571-8. PubMed ID: 15359116
[TBL] [Abstract][Full Text] [Related]
48. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
49. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
50. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
[TBL] [Abstract][Full Text] [Related]
51. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.
Dittadi R; Zancan M; Perasole A; Gion M
Int J Biol Markers; 2001; 16(4):255-61. PubMed ID: 11820721
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
54. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
[TBL] [Abstract][Full Text] [Related]
55. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
56. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
Thriveni K; Deshmane V; Bapsy PP; Krishnamoorthy L; Ramaswamy G
Indian J Med Res; 2007 Feb; 125(2):137-42. PubMed ID: 17431282
[TBL] [Abstract][Full Text] [Related]
57. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
[TBL] [Abstract][Full Text] [Related]
58. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
[TBL] [Abstract][Full Text] [Related]
59. Circulating levels of HER-2/neu oncoprotein in breast cancer.
Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
[TBL] [Abstract][Full Text] [Related]
60. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.
Stark A; Hulka BS; Joens S; Novotny D; Thor AD; Wold LE; Schell MJ; Melton LJ; Liu ET; Conway K
J Clin Oncol; 2000 Jan; 18(2):267-74. PubMed ID: 10637239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]